Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy

• Status: Terminated
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ACE inhibitor is more effective in reverse left ventricular remodeling in severe congestive heart failure in patients with nonischemic cardiomyopathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hebei Medical University
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• New York Heart Association (NYHA) Functional class Ⅲ or Ⅳ

• Left Ventricular Ejection Fraction (LVEF) <35%

• Nonischemic cardiomyopathy

• Preserved renal function: Cr ≤2.5 mg/dL in males; Cr ≤2.0mg/dL in females

Exclusion Criteria:

• Hyperkalemia (≥5.0 mEg/L)

• Left ventricular systolic dysfunction with pericardial diseases, congenital heart diseases, pulmonary heart diseases, heart valvular diseases, acute coronary syndrome and short life expectancy.